Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes
详细信息 查看全文
- 作者：Ivetta Danylesko ; Rina Sareli ; Nira Bloom-Varda ; Ronit Yerushalmi ; Noga Shem-Tov ; Avichai Shimoni ; Arnon Nagler ; Arnon.Nagler@sheba.health.gov.il" class="auth_mail" title="E-mail the corresponding author
- 关键词：Biosimilar ; Granulocyte colony&ndash ; stimulating factor (G-CSF) ; Allogeneic hematopoietic stem transplantation ; Normal donors ; Siblings ; Myelodysplastic syndromes ; Acute myelogenous leukemia
- 刊名：Biology of Blood and Marrow Transplantation
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：22
- 期：2
- 页码：277-283
- 全文大小：570 K
文摘
- •
Hemopoietic stem cell mobilization by XMO2 versus filgrastim is safe for HLA-matched sibling donors.
- •
We observed similar yields of stem cell collection, graft composition, and engraftment.
- •
We observed similar allogeneic stem cell transplantation outcomes in both groups in patients with acute myelogenous leukemia and myelodysplastic syndromes.